Agile Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $2.74 Mil. Agile Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $2.57 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Agile Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-6.78.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Agile Therapeutics's Days Inventory for the
three
months ended in Dec. 2023 was 107.22.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Agile Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Agile Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.71.
Agile Therapeutics Total Inventories Historical Data
The historical data trend for Agile Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Agile Therapeutics (OTCPK:AGRX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Agile Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Agile Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Agile Therapeutics Total Inventories Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics (Agile Therapeutics) Business Description
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 